Short-course Preoperative Chemoradiotherapy for Rectal Cancer (KROG 11-02)
This study is currently recruiting participants.
Verified September 2011 by Seoul St. Mary's Hospital
Sponsor:
Seoul St. Mary's Hospital
Collaborators:
Seoul National University Hospital
Samsung Medical Center
National Cancer Center, Korea
Information provided by (Responsible Party):
Jong Hoon Lee, Seoul St. Mary's Hospital
ClinicalTrials.gov Identifier:
NCT01431599
First received: September 6, 2011
Last updated: September 9, 2011
Last verified: September 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the early clinical outcome of the short-course preoperative chemoradiotherapy, 33Gy/10 fx and delayed operation after chemoradiation, the investigators initiated the clinical trial of KROG 11-02.
| Condition | Intervention | Phase |
|---|---|---|
|
Rectal Cancer |
Radiation: short-course radiation |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Two Week-course Preoperative Chemoradiotherapy Followed by Delayed Operation for Rectal Cancer: Phase II Multicenter Clinical Trial (KROG 11-02) |
Resource links provided by NLM:
Further study details as provided by Seoul St. Mary's Hospital:
Primary Outcome Measures:
- downstaging effect of tumor [ Time Frame: an expected average of 6 weeks after chemoradiation ] [ Designated as safety issue: No ]Comparison of clinical T staging and pathologic T staging example> cT4 --> pT1 after chemoradiation: down staging (+)
Secondary Outcome Measures:
- bladder and small bowel toxicity after chemoradiation [ Time Frame: Participants will be followed for an expected average of 3 months after chemoradiation ] [ Designated as safety issue: Yes ]The incidence of grade 3 or higher small bowel and bladder toxicity according to the RTOG and EORTC toxicity criteria (reference: Cox JD et al. Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6)
| Estimated Enrollment: | 80 |
| Study Start Date: | September 2011 |
| Estimated Study Completion Date: | October 2017 |
| Estimated Primary Completion Date: | October 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: short-course |
Radiation: short-course radiation
33Gy/10 fractions
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- histologically confirmed adenocarcinoma
- distal margin of the tumor located < 8 cm above the anal verge
- cT3-4 or cN+ classification as determined by endorectal ultrasonography (EUS) and CT
- patient older than age 18 years
- Karnofsky performance score >= 70
Exclusion Criteria:
- distant metastasis identified during staging workup
- previous or concurrent malignancy
- pregnant or breast-feeding women
- impending rectal obstruction
- familial adenomatous polyposis
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01431599
Contacts
| Contact: Jong Hoon Lee, MD | 82-010-8607-1269 | koppul@catholic.ac.kr |
Locations
| Korea, Republic of | |
| National Cancer Center, Korea | Recruiting |
| Goyang, Korea, Republic of | |
| Contact: Dae Yong Kim, MD radiopiakim@hanmail.net | |
| Seoul National University Hospital | Recruiting |
| Seoul, Korea, Republic of | |
| Contact: Eui Kyu Chie, MD ekchie93@SNU.ac.kr | |
| Samsung Medical Center | Recruiting |
| Seoul, Korea, Republic of | |
| Contact: Hee Chul Park, MD hee.ro.park@samsung.com | |
Sponsors and Collaborators
Seoul St. Mary's Hospital
Seoul National University Hospital
Samsung Medical Center
National Cancer Center, Korea
Investigators
| Principal Investigator: | Hong Seok Jang, MD | Department fo Radiation Oncology, Seoul St. Mary's Hospital |
More Information
Publications:
| Responsible Party: | Jong Hoon Lee, Dr., Seoul St. Mary's Hospital |
| ClinicalTrials.gov Identifier: | NCT01431599 History of Changes |
| Other Study ID Numbers: | KROG 11-02 |
| Study First Received: | September 6, 2011 |
| Last Updated: | September 9, 2011 |
| Health Authority: | Korea: Ministry for Health, Welfare and Family Affairs |
Keywords provided by Seoul St. Mary's Hospital:
|
Locally advanced rectal cancer |
Additional relevant MeSH terms:
|
Rectal Neoplasms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site |
Neoplasms Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases Rectal Diseases |
ClinicalTrials.gov processed this record on May 19, 2013